DURECT Corporation (NASDAQ:DRRX) Q4 2024 Earnings Conference Call March 26, 2025 4:30 PM ET
Company Participants
Tim Papp – Chief Financial Officer
Jim Brown – Co-Founder, Chief Executive Officer, President, Director
Norman Sussman – Chief Medical Officer
WeiQi Lin – Executive Vice President, Research & Development and Principal Scientist
Conference Call Participants
François Brisebois – Oppenheimer & Company
Karl Burns – Northland Capital Markets
Thomas Yip – H.C. Wainwright
Operator
Greetings and welcome to the DURECT Corporation Fourth Quarter and Full-Year 2024 Earnings Conference Call. At this time, all participants are in listen-only mode. A question-and-answer session will follow the formal presentation. [Operator Instructions] As a reminder, this conference is being recorded.
It’s now my pleasure to introduce Tim Papp, Chief Financial Officer.
Tim Papp
Good afternoon and welcome to DURECT Corporation’s Fourth Quarter 2024 Earnings Conference Call. This is Tim Papp, Chief Financial Officer of DURECT. Before we begin, I would like to remind you of our safe harbor statement.
During the course of this call, we may make forward-looking statements regarding DURECT’s products and development, expected product benefits, our development plans, future clinical trials, or projected financial results. These forward-looking statements involve risks and uncertainties that can cause actual results to differ materially from those in such forward-looking statements. Further information regarding these and other risks can be found in our SEC filings, including our 10-K and 10-Qs under the heading Risk Factors.
To begin, I would like to review our fourth quarter and full-year 2024 financial results. The following financial information relates solely to our continuing operations and therefore does not include the operations of our ALZET product line which we sold in the fourth quarter of 2024.
Total revenues in 2024 were $2 million, compared with $2.6 million in 2023 and $0.5 million for the fourth quarter of 2024, compared to $0.9
Read the full article here
